Researchers Identified Pancreatic Cancer Drug Resistance
A new study reveals how cancer cells bypass the effects of the FDA-approved treatment daraxonrasib.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Should medical research prioritize developing new drugs or combining existing cancer therapies?
Researchers have discovered that pancreatic cancer cells can develop resistance to the drug daraxonrasib by overproducing the KRAS protein. The findings follow the drug's approval in August 2026 and reports from former Senator Ben Sasse, whose own cancer became resistant to the treatment.
Why it matters
Understanding how tumors evade daraxonrasib is critical for improving patient outcomes, as the medication typically stops working after seven months. These insights could lead to more effective treatment strategies, such as combining drugs to prevent resistance.
A study of 66 patients showed daraxonrasib reduces cancer cell counts by half within two weeks, though resistance typically emerges after seven months. Researchers are currently tracking over 90 different KRAS inhibitors in various stages of clinical trials.
The players
Ben Sasse
The former United States Senator for Nebraska publicly shared that his pancreatic cancer ceased responding to daraxonrasib.
Dana-Farber Cancer Institute
This Boston-based research center is a leading institution in the study and treatment of complex cancer cases.
The details
By analyzing biopsies from 66 patients and blood samples from 44, researchers identified that surviving tumor cells mirror those that typically respond to chemotherapy. The cells evade treatment by specifically increasing their production of the KRAS protein.
Timeline
Daraxonrasib received official drug approval in August 2026.
Ben Sasse announced his cancer developed drug resistance in September 2026.
Study results were presented at an AACR conference on September 25, 2026.
The Big Picture
This study updates the current clinical trials pipeline for KRAS inhibitors by identifying a specific mechanism of therapeutic failure. The findings represent a shift in focus toward combination therapies to address the limitations of targeting the KRAS protein alone.
Patients currently undergoing daraxonrasib treatment may need to discuss emerging resistance risks with their oncologists to prepare for potential changes in therapy. The research highlights the importance of clinical trial participation for those seeking options beyond standard KRAS inhibitor protocols.
The takeaway
Researchers are actively exploring whether dual-inhibitor treatments or chemotherapy combinations can sustain the effectiveness of daraxonrasib. Patients should consult their healthcare providers regarding the latest developments in targeted cancer protein therapy.
Further reading
For more on the current landscape of oncology research, visit the Cancer section.
Source note: This article includes information reported by The New York Times.
Live Poll
Should medical research prioritize developing new drugs or combining existing cancer therapies?
